Journal of Otolaryngology and Ophthalmology of Shandong University ›› 2020, Vol. 34 ›› Issue (3): 75-80.doi: 10.6040/j.issn.1673-3770.1.2020.022

Previous Articles    

Clinical effect of Hashimoto thyroiditis on the ratio of BRAFV600E alleles in papillary thyroid carcinoma

NI Yeqin1, WU Fan1, XUN Yanping2, ZHAO Pan3, ZHANG Shirong2, ZHOU Tianhan1, SUN Sihan4, LU Kaining4, LUO Dingcun5   

  1. 1. The Fourth Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou 310006, Zhejiang, China;
    2. Centre of Translational Medicine, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou 310006, Zhejiang, China;
    3. Department of Pathology, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou 310006, Zhejiang China;
    4. Nanjing Medical University Nanjing 210000, Jiangsu, China;
    5. Department of Surgical Oncology, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou 310006, Zhejiang, China;
  • Published:2020-06-29

Abstract: Objective To evaluate the clinical effect of Hashimoto thyroiditis(HT)on the ratio of BRAFV600E alleles in papillary thyroid carcinoma(PTC). Methods Two hundred and forty-two patients who underwent surgery at our hospital between December 2017 and December 2019 were enrolled in this study. The ratio of BRAFV600E alleles was measured using droplet digital PCR and formalin-fixed paraffin-embedded tissues, and its correlation with HT was analyzed. Using propensity score matching and based on the 63 patients with HT(1∶1), 179 PTC patients without HT during the same period were retrospectively enrolled as controls. Results There was a significant difference between the ratio of BRAFV600E alleles(P<0.001)of the two groups(PTC patients with HT versus those without HT); the rates of positive-BRAFV600E were not significantly different(87.3% vs 92.7%, P>0.05). After propensity score matching, the significant difference between the two groups at baseline was no longer observed. The ratio of BRAFV600E alleles was still significantly lower in patients with HT(median 3.20%)than in those without HT(median 9.00%, P=0.001). Conclusion HT can significantly reduce the ratio of BRAFV600E alleles in PTC, and this has an important effect on PTC progression and prognosis.

Key words: Thyroid neoplasms, Propensity score matching, Hashimoto thyroiditis, Ratio of BRAFV600E alleles

CLC Number: 

  • R604
[1] Xing MZ, Alzahrani AS, Carson KA, et al. Association between BRAFV600E mutation and recurrence of papillary thyroid cancer[J]. J Clin Oncol, 2015, 33(1): 42-50. doi:10.1200/JCO.2014.56.8253.
[2] Jankovic B, Le KT, Hershman JM. Clinical Review: Hashimoto's thyroiditis and papillary thyroid carcinoma: is there a correlation?[J]. J Clin Endocrinol Metab, 2013, 98(2): 474-482. doi:10.1210/jc.2012-2978.
[3] Golden SH, Robinson KA, Saldanha I, et al. Clinical review: Prevalence and incidence of endocrine and metabolic disorders in the United States: a comprehensive review[J]. J Clin Endocrinol Metab, 2009, 94(6): 1853-1878. doi:10.1210/jc.2008-2291.
[4] Lee YK, Park KH, Park SH, et al. Association between diffuse lymphocytic infiltration and papillary thyroid cancer aggressiveness according to the presence of thyroid peroxidase antibody and BRAFV600E mutation[J]. Head Neck, 2018, 40(10): 2271-2279. doi:10.1002/hed.25327.
[5] Kwak HY, Chae BJ, Eom YH, et al. Does papillary thyroid carcinoma have a better prognosis with or without Hashimoto thyroiditis?[J]. Int J Clin Oncol, 2015, 20(3): 463-473. doi:10.1007/s10147-014-0754-7.
[6] Zhang Q, Liu BJ, Ren WW, et al. Association between BRAFV600E mutation and ultrasound features in papillary thyroid carcinoma patients with and without hashimoto's thyroiditis[J]. Sci Rep, 2017, 7(1): 4899. doi:10.1038/s41598-017-05153-y.
[7] Marotta V, Guerra A, Zatelli MC, et al. BRAF mutation positive papillary thyroid carcinoma is less advanced when Hashimoto's thyroiditis lymphocytic infiltration is present[J]. Clin Endocrinol(Oxf), 2013, 79(5): 733-738. doi:10.1111/cen.12194.
[8] Ylli D, Patel A, Jensen K, et al. Microfluidic droplet digital PCR is a powerful tool for detection of BRAF and TERT mutations in papillary thyroid carcinomas[J]. Cancers(Basel), 2019, 11(12): E1916. doi:10.3390/cancers11121916.
[9] 倪烨钦, 荀延萍, 赵盼,等. BRAFV600E突变比值在预测甲状腺乳头状癌颈部淋巴结转移中的临床价值[J]. 国际耳鼻咽喉头颈外科杂志. 2020, 44(1):6-10. doi:10.3760/cma.j.issn.1673-4106.2020.01.002 NI Yeqin, XUN Yanping, ZHAO Pan, et al. Clinical value of the ratio of BRAFV600E expression for predicting lymph node metastasis in papillary thyroid carcinoma[J]. International Journal of Dermatology and Venereology, 2020, 44(1):6-10. doi:10.3760/cma.j.issn.1673-4106.2020.01.002
[10] Guan HX, de Morais NS, Stuart J, et al. Discordance of serological and sonographic markers for Hashimoto's thyroiditis with gold standard histopathology[J]. Eur J Endocrinol, 2019, 181(5): 539-544. doi:10.1530/EJE-19-0424.
[11] 中华医学会内分泌学分会《中国甲状腺疾病诊治指南》编写组. 中国甲状腺疾病诊治指南——甲状腺炎:亚急性甲状腺炎[J]. 中华内科杂志. 2008, 47(9):784-785.
[12] Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects[J]. Biometrika, 1983, 70(1): 41-55. doi:10.1093/biomet/70.1.41.
[13] Lee JH, Kim Y, Choi JW, et al. The association between papillary thyroid carcinoma and histologically proven Hashimoto's thyroiditis: a meta-analysis[J]. Eur J Endocrinol, 2013, 168(3): 343-349. doi:10.1530/EJE-12-0903.
[14] Liang J, Zeng W, Fang F, et al. Clinical analysis of Hashimoto thyroiditis coexistent with papillary thyroid cancer in 1392 patients[J]. Acta Otorhinolaryngol Ital, 2017, 37(5): 393-400. doi:10.14639/0392-100X-1709.
[15] Riesco-Eizaguirre G, Rodríguez I, De la Vieja A, et al. The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer[J]. Cancer Res, 2009, 69(21): 8317-8325. doi:10.1158/0008-5472.CAN-09-1248.
[16] Xing MZ, Alzahrani AS, Carson KA, et al. Association between BRAFV600E mutation and mortality in patients with papillary thyroid cancer[J]. JAMA, 2013, 309(14): 1493-1501. doi:10.1001/jama.2013.3190.
[17] Kimura ET, Nikiforova MN, Zhu ZW, et al. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma[J]. Cancer Res, 2003, 63(7): 1454-1457.
[18] Xing M. BRAF mutation in thyroid cancer[J]. Endocr Relat Cancer, 2005, 12(2): 245-262. doi:10.1677/erc.1.0978.
[19] Li XY, Li EL, Du J, et al. BRAF mutation analysis by ARMS-PCR refines thyroid nodule management[J]. Clin Endocrinol(Oxf), 2019, 91(6): 834-841. doi:10.1111/cen.14079.
[20] Ren HY, Shen YF, Hu DX, et al. Co-existence of BRAFV600E and TERT promoter mutations in papillary thyroid carcinoma is associated with tumor aggressiveness, but not with lymph node metastasis[J]. Cancer Manag Res, 2018, 10: 1005-1013. doi:10.2147/CMAR.S159583.
[21] Olmedillas-López S, García-Arranz M, García-Olmo D. Current and emerging applications of droplet digital PCR in oncology[J]. Mol Diagn Ther, 2017, 21(5): 493-510. doi:10.1007/s40291-017-0278-8.
[22] Muzza M, Degl'Innocenti D, Colombo C, et al. The tight relationship between papillary thyroid cancer, autoimmunity and inflammation: clinical and molecular studies[J]. Clin Endocrinol(Oxf), 2010, 72(5): 702-708. doi:10.1111/j.1365-2265.2009.03699.x.
[23] Colombo C, Muzza M, Proverbio MC, et al. Impact of mutation density and heterogeneity on papillary thyroid cancer clinical features and remission probability[J]. Thyroid, 2019, 29(2): 237-251. doi:10.1089/thy.2018.0339.
[24] Guerra A, Sapio MR, Marotta V, et al. The primary occurrence of BRAF(V600E)is a rare clonal event in papillary thyroid carcinoma[J]. J Clin Endocrinol Metab, 2012, 97(2): 517-524. doi:10.1210/jc.2011-0618.
[1] SONG Xiaoyu, SONG Xicheng. Research progress on the regulation of HIF-1α expression in thyroid carcinoma [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2019, 33(2): 136-138.
[2] FANG Jugao. Operation skill and standard diagnosis and treatment are the basics of improving the curative effect of thyroid carcinoma. [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2016, 30(2): 1-4.
[3] LIU Xin-yi,LIU Yan,LI Song-jun,LI Da-jian,XUE Ling-jun . Clinical features and early diagnosis of thyroid micro-carcinoma [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2008, 22(1): 29-31 .
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!